Cutaneous infection by Mycobacterium haemophilum and kansasii in an IgA-deficient man.
BACKGROUND
The prevalence of infections by nontuberculous mycobacteria (NTM) has steadily increased over the past decades, especially in immunocompromised patients.


METHODS
We present a patient with IgA-deficiency and mixed cutaneous infection by two slowly growing mycobacteria, Mycobacterium (M.) haemophilum and M. kansasii.


CONCLUSIONS
Cutaneous M. haemophilum infections most often result from HIV or transplantation-associated immunosuppression. Rarely, M. haemophilum may also infect healthy patients or iatrogenically immunosuppressed patients without transplantation. M. kansasii is one of the most frequent NTM and large awareness exists about its involvement in human diseases. Mycobacterial diagnosis of cutaneous infections should be considered in long-lasting skin lesions.
Department of Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany. vbek777@gmail.com
Vassiliki
V
Bekou
Amanda
A
Büchau
Michael J
MJ
Flaig
Thomas
T
Ruzicka
Michael
M
Hogardt
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001706:Biopsy; D017291:Clarithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D017098:IgA Deficiency / Q000150:complications*; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D009164:Mycobacterium Infections / Q000150:complications* / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D018393:Mycobacterium haemophilum / Q000254:growth & development / Q000302:isolation & purification*; D019909:Mycobacterium kansasii / Q000254:growth & development / Q000302:isolation & purification*; D017828:Rifabutin / Q000008:administration & dosage / Q000627:therapeutic use; D017192:Skin Diseases, Bacterial / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology / Q000473:pathology
D000900:Anti-Bacterial Agents; D017828:Rifabutin; D004977:Ethambutol; D017291:Clarithromycin
Dermatol Clin. 2009 Jan;27(1):63-73
18984369
Postepy Hig Med Dosw (Online). 2006;61:38-47
17369772
Kekkaku. 2003 Nov;78(11):705-9
14672048
Dermatologica. 1984;168(5):230-2
6724079
J Clin Microbiol. 2006 May;44(5):1769-75
16672405
J Pathol. 2006 Jan;208(2):270-82
16362985
J Clin Immunol. 2010 Jan;30(1):10-6
20101521
Vaccine. 2005 Apr 8;23(20):2565-72
15780438
Kekkaku. 2005 Apr;80(4):359-64
15991601
Adv Immunol. 1997;65:245-76
9238511
J Clin Microbiol. 2000 Sep;38(9):3231-4
10970363
Diagn Microbiol Infect Dis. 2000 Nov;38(3):173-5
11109017
J Formos Med Assoc. 2002 Aug;101(8):581-4
12440090
J Allergy Clin Immunol. 1994 Aug;94(2 Pt 1):195-200
8064071
Int Arch Allergy Immunol. 2008;147(2):87-92
18520152
South Med J. 2002 Sep;95(9):1095-8
12356122